Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 17 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Obstructive sleep apnea is characterized by disordered breathing during sleep and is associated with major cardiovascular complications; excess adiposity is an etiologic risk factor. Tirzepatide may be a potential treatment. METHODS: We conducted two phase 3, double-blind, randomized, controlled trials involving adults with moderate-to-severe obstructive sleep apnea and obesity. Participants who were not receiving treatment with positive airway pressure (PAP) at baseline were enrolled in trial 1, and those who were receiving PAP therapy at baseline were enrolled in trial 2. The participants were assigned in a 1:1 ratio to receive either the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or placebo for 52 weeks. The primary end point was the change in the apnea-hypopnea index (AHI, the number of apneas and hypopneas during an hour of sleep) from baseline. Key multiplicity-controlled secondary end points included the percent change in AHI and body weight and changes in hypoxic burden, patient-reported sleep impairment and disturbance, high-sensitivity C-reactive protein (hsCRP) concentration, and systolic blood pressure. RESULTS: At baseline, the mean AHI was 51.5 events per hour in trial 1 and 49.5 events per hour in trial 2, and the mean body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) was 39.1 and 38.7, respectively. In trial 1, the mean change in AHI at week 52 was -25.3 events per hour (95% confidence interval [CI], -29.3 to -21.2) with tirzepatide and -5.3 events per hour (95% CI, -9.4 to -1.1) with placebo, for an estimated treatment difference of -20.0 events per hour (95% CI, -25.8 to -14.2) (P<0.001). In trial 2, the mean change in AHI at week 52 was -29.3 events per hour (95% CI, -33.2 to -25.4) with tirzepatide and -5.5 events per hour (95% CI, -9.9 to -1.2) with placebo, for an estimated treatment difference of -23.8 events per hour (95% CI, -29.6 to -17.9) (P<0.001). Significant improvements in the measurements for all prespecified key secondary end points were observed with tirzepatide as compared with placebo. The most frequently reported adverse events with tirzepatide were gastrointestinal in nature and mostly mild to moderate in severity. CONCLUSIONS: Among persons with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide reduced the AHI, body weight, hypoxic burden, hsCRP concentration, and systolic blood pressure and improved sleep-related patient-reported outcomes. (Funded by Eli Lilly; SURMOUNT-OSA ClinicalTrials.gov number, NCT05412004.).
Overview
CoChat Summary
## TL;DR
In two 52-week phase 3 randomized controlled trials of adults with moderate-to-severe obstructive sleep apnea and obesity, tirzepatide improved apnea-hypopnea index (AHI) and multiple secondary outcomes versus placebo. The paper concludes that tirzepatide reduced sleep-disordered breathing, body weight, hypoxic burden, hsCRP, systolic blood pressure, and improved sleep-related patient-reported outcomes.
## Key findings
- In trial 1, the mean change in AHI at week 52 was -25.3 events/hour with tirzepatide versus -5.3 events/hour with placebo; the estimated treatment difference was -20.0 events/hour (95% CI, -25.8 to -14.2; P<0.001).
- In trial 2, the mean change in AHI at week 52 was -29.3 events/hour with tirzepatide versus -5.5 events/hour with placebo; the estimated treatment difference was -23.8 events/hour (95% CI, -29.6 to -17.9; P<0.001).
- In the pooled analysis, participants receiving tirzepatide had significant reductions in PROMIS-SRI and PROMIS-SD T scores, and both trials showed significant reductions in body weight, systolic blood pressure, and hsCRP concentrations.
- The paper states that the most frequently reported adverse events with tirzepatide were gastrointestinal and generally mild-to-moderate; adverse events occurred in 79.8% vs 76.7% of participants in trial 1 and 83.2% vs 72.8% in trial 2 (tirzepatide vs placebo).
## Methods
- Two 52-week, phase 3, multicenter, parallel-group, double-blind, randomized, controlled trials were conducted at 60 sites across nine countries.
- Adults with moderate-to-severe obstructive sleep apnea (AHI ≥15 events/hour) and obesity (BMI ≥30; ≥27 in Japan) were enrolled; trial 1 included participants unable or unwilling to use PAP, and trial 2 included participants using PAP for at least 3 consecutive months and planning to continue.
- Participants were randomized 1:1 to weekly tirzepatide (10 mg or 15 mg maximum tolerated dose) or placebo; the primary endpoint was change in AHI from baseline, with key secondary endpoints including AHI percent change, body weight, hypoxic burden, hsCRP, patient-reported sleep outcomes, and systolic blood pressure. Analyses used ANCOVA and logistic regression, with multiplicity control via a graphical testing procedure.
## Limitations
- The paper states that the shorter duration of the trials does not support assessment of long-term cardiovascular outcomes.
- The trials excluded participants without obesity and did not assess people with overweight or normal BMI.
- The trials were not designed to test whether results differed by baseline symptoms, and trial 2 was not designed to assess PAP adherence effects; also, the minimum clinically important changes for PROMIS-SRI and PROMIS-SD were not established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 0 Not valid · 6 Not checked · 57 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Excess adiposity is a major reversible etiologic risk factor for obstructive sleep apnea and its complications. 8,9”
What the sources say
- Supportedcites [8] 8. Hudgel DW, Patel SR, Ahasic AM, et al. The role of weight management in the treatment of adult obstructive sleep apnea: an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2018;198(6):e70-e87. [PubMed: 30215551] source
The Introduction says weight gain is linked to the development and worsening of OSA and that obesity aggravates its metabolic and cardiovascular comorbidities. “Putting It All Together” reports that weight loss consistently improves OSA severity and may improve associated health outcomes, supporting reversibility. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [9] 9. Morgenthaler TI, Kapen S, Lee-Chiong T, et al. Practice parameters for the medical therapy of obstructive sleep apnea. Sleep 2006;29:1031-5. [PubMed: 16944671] source
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This level of weight reduction has been difficult to accomplish with lifestyle intervention alone. 35”
What the sources say
- Partly supportedcites [35] 35. Dombrowski SU, Knittle K, Avenell A, Araújo-Soares V, Sniehotta FF. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ 2014;348:g2646. [PubMed: 25134100] sourceExperimental — accuracy not yet measured
The Introduction says few people maintain weight loss over the long term, and the Behavioural/lifestyle v control section reports a modest mean difference of −1.56 kg at 12 months. This supports the general difficulty of sustaining weight loss with lifestyle intervention, but the claim does not specify what “this level” is, so the paper cannot verify that particular level. (LLM, conf=0.78)
- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The potential issue of PAP confounding of the PROMIS outcomes in trial 2 was minimized by a 7-day PAP washout period. 22”
What the sources say
- Partly supportedcites [22] 22. Schwarz EI, Stradling JR, Kohler M. Physiological consequences of CPAP therapy withdrawal in patients with obstructive sleep apnoea-an opportunity for an efficient experimental model. J Thorac Dis 2018;10:Suppl 1:S24-S32. [PubMed: 29445525] sourceExperimental — accuracy not yet measured
The Physiological effects of CPAP withdrawal section reports that OSA recurred and subjective sleepiness increased one week after CPAP withdrawal, supporting the rationale for a washout. It does not assess PROMIS outcomes or establish that seven days minimized PAP confounding in trial 2; sleepiness continued to increase at two weeks. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The safety profile of tirzepatide was consistent with that observed in previous trials. 14,3739”
What the sources say
- Not checked — no full text of the sourcecites [14] 14. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022;387:205-16. [PubMed: 35658024] source
- Supportedcites [37] 37. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebocontrolled, phase 3 trial. Lancet 2023;402:613-26. [PubMed: 37385275] source
The Discussion explicitly states that tirzepatide’s safety profile was consistent with previous findings in the SURMOUNT-1 and SURPASS trials. The Safety section also describes the adverse events observed in this trial. (LLM, conf=0.95)
- Supportedcites [38] 38. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med 2023;29:2909-18. [PubMed: 37840095] source
The Discussion explicitly states that tirzepatide’s safety profile in this trial was consistent with findings from previous tirzepatide trials. It also notes modestly higher rates of gastrointestinal adverse events and treatment discontinuation than in the tirzepatide 15 mg group in SURMOUNT-1; that qualification does not negate the overall comparison. (LLM, conf=0.95)
- Partly supportedcites [39] 39. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38-48. [PubMed: 38078870] sourceExperimental — accuracy not yet measured
The Results (Adverse Events and Tolerability; page unavailable) describe tirzepatide’s safety findings, including gastrointestinal events and serious adverse events. The passages do not compare that safety profile with previous trials, so the claimed consistency with earlier findings is not established by our copy. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were five cases of severe or serious depressive disorder or suicidal ideation or behavior events across both trials (two with tirzepatide and three with placebo).”
plainn = 5- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
29 more claims
Create a free account to see all 77 claims and every source verdict.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 31
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“However, some studies were designed for other purposes17,18,30,41–44—for example, prevention of CVD or T2D.”
From A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults (2025) · cites this paper as [43]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These medications allow most patients to achieve clinically meaningful weight loss, improve severity of OSA, and improve cardiometabolic comorbidities.13,14”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These medications allow most patients to achieve clinically meaningful weight loss, improve severity of OSA, and improve cardiometabolic comorbidities.13,14”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These medications allow most patients to achieve clinically meaningful weight loss, improve severity of OSA, and improve cardiometabolic comorbidities.13,14”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SURMOUNT-OSA trial reported that tirzepatide reduced the apnea-hypopnea index by 25% to 29% over 52 weeks in individuals with obesity and moderate to severe OSA, compared with a reduction of 5.3% to 5.5% in the placebo group, regardless of the use of positive airway pressure therapy (19).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Benjafield, A. V., Ayas, N. T., Eastwood, P. R., Heinzer, R., Ip, M. S. M., Morrell, M. J., Nunez, C. M., Patel, S. R., Penzel, T., Pépin, J.-L., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30198-5 · Cited by 4,326
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationAdult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine, Epstein, L. J., Kristo, D., Strollo, P. J., Friedman, N., Malhotra, A., Patil, S. P., Ramar, K., Rogers, R., Schwab, R. J., et al. (2009) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27497 · Cited by 3,360
Self-citationCPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea
McEvoy, R. D., Antic, N. A., Heeley, E., Luo, Y., Ou, Q., Zhang, X., Mediano, O., Chen, R., Drager, L. F., Liu, Z., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606599 · Cited by 2,101
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Adult obstructive sleep apnoea
Jordan, A. S., McSharry, D. G., & Malhotra, A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60734-5 · Cited by 1,735
Self-citationJavaheri, S., Barbe, F., Campos-Rodriguez, F., Dempsey, J. A., Khayat, R., Javaheri, S., Malhotra, A., Martinez-Garcia, M. A., Mehra, R., Pack, A. I., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.069 · Cited by 1,434
Self-citationYeghiazarians, Y., Jneid, H., Tietjens, J. R., Redline, S., Brown, D. L., El-Sherif, N., Mehra, R., Bozkurt, B., Ndumele, C. E., Somers, V. K., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000988 · Cited by 1,431
Self-citationRamar, K., Dort, L. C., Katz, S. G., Lettieri, C. J., Harrod, C. G., Thomas, S. M., & Chervin, R. D. (2015) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.4858 · Cited by 915
Azarbarzin, A., Sands, S. A., Stone, K. L., Taranto-Montemurro, L., Messineo, L., Terrill, P. I., Ancoli-Israel, S., Ensrud, K., Purcell, S., White, D. P., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy624 · Cited by 893
Self-citation
Cited by
Items 401–500 of 823
Tirzepatide: A Breakthrough Therapy for Obstructive Sleep Apnea and Metabolic Dysfunction
Singh, G., Jaswal, T., Kosey, S., Kumar, R., & Kaur, A. (2025) · Current Hypertension Reviews · doi:10.2174/0115734021398680251001102514 · Cited by 2
Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea
Qian, B., Huang, Y., Yan, C. X., Feng, S., & She, D. (2025) · Obesity Science & Practice · doi:10.1002/osp4.70090 · Cited by 1
Emerging dental therapies for sleep disorders
Simmons, M., Sheats, R. D., & Cruz, M. G. M. E. (2026) · The Journal of the American Dental Association · doi:10.1016/j.adaj.2025.10.010 · Cited by 3
Warden, B. A., Duell, P. B., Bucheit, J. D., & Purnell, J. Q. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.013 · Cited by 1
D’Alessio, D. A., & Kahn, S. E. (2024) · Diabetes · doi:10.2337/dbi24-0046 · Cited by 1
GLP ‐1‐Based Therapy for Obstructive Sleep Apnoea
Zheng, Y., & Yee, B. J. (2026) · Respirology · doi:10.1002/resp.70282 · Cited by 1
Assessment of Abdominal Adiposity in OSA Using Combined PET Imaging and MRI
Prevot, J., Xu, B., Patel, H. J., Fauveau, V., Lee, J. H., Cohen, O., Khan, S., Robson, P. M., Greenspan, H. K., Suárez-Fariñas, M., et al. (2026) · CHEST Journal · doi:10.1016/j.chest.2026.02.031 · Cited by 1
Kokkinos, A. D., Thethi, T. K., Lee, C. J., Neff, L. M., Stefański, A., Cao, D., Rodríguez, Á., & Bartee, A. K. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71009 · Cited by 2
Florescu, A.-R., Mihaicuta, S. D., Frent, S., Deleanu, O., Birză, M. R., Popa, A. M., Manzur, A. R., Gligor, L. N., & Bikov, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-80113-x · Cited by 1
Jalan, A., Murzinski, E. S., Jansen, P. J., Miller, R. D., Embry, M. C., Scherer, R. B., Moomaw, J. F., Williams, K. M., Fisher, C. A., James, J., et al. (2025) · Angewandte Chemie · doi:10.1002/ange.202520060 · Cited by 2
Stahl, S. M. (2026) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/cont.0000000000001722 · Cited by 1
Sleep Disturbances in Menopause: Neuroendocrine Mechanisms and Clinical Implications
Tamanna, S., Ullah, M. I., Iftekhar, R., & Shamsuddin, L. (2026) · Physiologia · doi:10.3390/physiologia6020022 · Cited by 4
Ciudin, A., Baker, J. L., Belančić, A., Busetto, L., Diker, D., Fábryová, Ľ., Frühbeck, G., Goossens, G. H., Gordon, J., Monami, M., et al. (2026) · medRxiv · doi:10.64898/2026.04.19.26351196 · Cited by 1
Joy, E., & Bonnet, J. P. (2026) · American Journal of Lifestyle Medicine · doi:10.1177/15598276261450530 · Cited by 1
Gonzalo Labarca, T., Henríquez‐Beltrán, M., & Solomons, D. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2591-5502 · Cited by 2
Cardiometabolic and Diabetes Management in Older Adults
Marion, W., & Neeland, I. J. (2026) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.12.005 · Cited by 1
Xue, Y., Liu, J., Raza, F., Zafar, H., Zhao, H., Li, R., & Liu, Z. (2025) · Nanoscale Advances · doi:10.1039/d5na00521c · Cited by 3
Therapiemanagement von Patienten mit obstruktiver Schlafapnoe: Status und Strategien zur Optimierung
Arzt, M. E., Schoebel, C., Galetke, W., Woehrle, H., & Somnexus-Gruppe (2025) · Somnologie - Schlafforschung und Schlafmedizin · doi:10.1007/s11818-025-00510-w · Cited by 3
Medications for Obstructive Sleep Apnea
Macanian, J., Schechter, N., & Frishman, W. H. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001148 · Cited by 1
Clinical considerations in the management of obesity in children and adolescents
Herring, W., Kugelmas, C., Nadler, E. P., Novick, M. B., Santos, M., Shah, R. D., Srivastava, G., & Walsh, S. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100160 · Cited by 1
Kumar, A., Scroggie, S., Sarkar, T. D., Hepokoski, M., & Malhotra, A. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2561067 · Cited by 1
Self-citationAdvances in Non-CPAP Management of Obstructive Sleep Apnea: Spotlight on Pharmacological Therapies
Siciliano, M., de Scisciolo, M., Fratini, A., Sottani, C., Giordani, F., & Brunetti, V. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16020105 · Cited by 2
Receipt of weight management services among patients with OSA and obesity
Leonhard, A. G., McDowell, J., Hoerster, K. D., Hayes, S., Picazo, F., Castaneda, J. M., Josey, K., Griffith, M., Ma, J., Duan, K. I., et al. (2025) · CHEST Pulmonary · doi:10.1016/j.chpulm.2025.100156 · Cited by 1
Kalaydzhiev, P., Velikova, T. V., Voynova, G., Ilieva, R., Spasova, N., Yakov, S., Kinova, E., Vasilev, G., Wells, R. N., & Goudev, A. (2025) · Pharmacia · doi:10.3897/pharmacia.72.e166690 · Cited by 1
Dynamic lock-in compensation for mechanically dithered ring laser gyros
樊振方, 罗晖, 卢广峰, & 胡绍民 (2012) · Chinese Optics Letters · Cited by 1
The Obesity–OSA–Arrhythmia Axis: Pathophysiological Mechanisms and Translational Therapeutic Targets
Cacciapuoti, F., Caso, I., Buonomo, A., Crispo, S., Taglialatela, V., Carpinella, G., Volpicelli, M., & Mauro, C. (2026) · Life · doi:10.3390/life16050737 · Cited by 2
Healy, W. J., Kundel, V., Taub, P. R., Cho, Y., Healy, S. J., & Kwon, Y. (2024) · SLEEP Advances · doi:10.1093/sleepadvances/zpae094 · Cited by 1
Esmaeel, M. N., Esmaeel, N. N., Alhouli, R., Alghareeb, N. M., Bucheery, R. A. A., Booresli, Y. W., Alasoosi, R. A., Alasoosi, B. A., Alrashidi, A. J., & Alawainati, M. (2026) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1811_25 · Cited by 2
Shakkottai, A., & Firdaus, M. (2025) · Springer eBooks · doi:10.1007/978-3-031-92166-7_9 · Cited by 1
Tirzepatide: a dual approach to combat obesity and obstructive sleep apnea
Naseem, S., Afreen, S., Fareha, S., Pushpa, C., & Reja, M. H. (2025) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20252496 · Cited by 1
Saraiva, J. F. K., Valério, C. M., Rached, F. H., van de Sande‐Lee, S., Rocha, V. Z., Valente, F., Drager, L. F., Halpern, B., Júnior, W. S. D. S., Trujilho, F. R., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250621 · Cited by 17
Tripipitsiriwat, A., Malhotra, A., Robertson, H., Kim, N. H., Yang, J. Z., & Raphelson, J. R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155442 · Cited by 2
Self-citationMediano, O., & Masa, J. F. (2025) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2025.03.009 · Cited by 3
A New Era in the Medical Management of Obesity
Porterfield, F., Fatima, A., Boaventura, B. C. B., Madhar, A., Srivastava, G., & Stanford, F. C. (2026) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-125437 · Cited by 3
Medicatie voor obesitas: vooruitgang en uitdagingen
Muskiet, M. H. A., & Boon, M. R. (2024) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-024-1569-4 · Cited by 1
Tackling a Lifetime of Risk for OSA
Shah, N. M., & Suh, E. (2025) · Respirology · doi:10.1111/resp.70025 · Cited by 1
Piťhová, P. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.009 · Cited by 1
Glucagon-like Peptide 1 Receptor Agonists and Obesity Associated with Eating Disorders
Grave, R. D. (2024) · IJEDO · doi:10.32044/ijedo.2024.02 · Cited by 1
Zheng, Y., Piper, A. J., Wong, K., Gauthier, G., Phillips, C. L., Grunstein, R. R., & Yee, B. J. (2025) · Respirology · doi:10.1002/resp.70151 · Cited by 1
Self-citationThe association of obesity with cardiovascular disease risk and risk-enhancing factors
Paparodis, R. D., Bantouna, D., Livadas, S., & Angelopoulos, N. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.08.018 · Cited by 6
Therapeutic potential of GLP-1RAs in sleep apnea with genetic associations to type 2 diabetes
Cheng, F., Yang, K., Wang, Y., Yang, F., Niu, X., & Li, W. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01699-4 · Cited by 1
Untreated obstructive sleep apnea and accelerated cognitive decline over 10 years
Kaufmann, C. N., Albrecht, J. S., Sekhon, V. K., Gross, A. L., Wickwire, E. M., Amjad, H., Roth, D. L., Malhotra, A., Blinka, M. D., Chen, X., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71533 · Cited by 1
Self-citationRadu, D., Parlițeanu, O.-A., Nica, A. E., Voineag, C., Alexe, O., Cristea, A. M., Georgescu, L., Nemeş, R. M., Tiron, A. T., & Nemeş, A. F. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15080336 · Cited by 5
Shrestha, R., Kovacevich, A., Yerneni, H., Shroff, P., & Sajatovic, M. (2026) · Psychiatric Annals · doi:10.3928/00485713-20260701-01 · Cited by 1
Khan, I., Meenakshi, S., Abubakar, M., Kumar, N., Gaikwad, V. L., Rai, A., & Murti, K. (2026) · Endocrine · doi:10.1007/s12020-026-04686-5 · Cited by 2
Bayram, F., Hegner, P., Lauerer, A.-M., Schildt, S., Wermers, D., Baier, M. J., Mustroph, J., Tafelmeier, M., Provazník, Z., Schmid, C., et al. (2025) · Antioxidants · doi:10.3390/antiox14020163 · Cited by 2
Obesity and respiratory diseases: mechanisms, phenotypes, and clinical implications
Soliman, A. M., Abouzeid, A., & Ahmed, H. H. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02164-6 · Cited by 3
Uncovering the role of sleep on human health
Mazzotti, D. R., & Manetta, M. (2025) · Nature Medicine · doi:10.1038/s41591-025-03529-6 · Cited by 1
Liu, L., Tang, P., Chiu, J. W.-T., Dong, Z., Wang, C., Huang, W., & Chen, W. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08723-0 · Cited by 1
Anderson, B. J., Daele, D. J. V., Claussen, A. D., Tanenbaum, Z. G., & Owen, S. R. (2026) · Annals of Otology Rhinology & Laryngology · doi:10.1177/00034894261450724 · Cited by 1
Verde, L., Coletta, D. K., Klimentidis, Y. C., Kohler, L. N., SOLTANI, L. F., Parra, O. D., Parthasarathy, S., Mandarino, L. J., & Muscogiuri, G. (2025) · Nutrients · doi:10.3390/nu17152476 · Cited by 2
Impact of Bariatric Surgery on Hypoglossal Nerve Stimulation Outcomes
Kaki, P. C., Wesson, T., Choi, A. Y., Shah, S., Kaffenberger, T. M., Soose, R. J., Parker, N. P., Boon, M. S., Huntley, C. T., & Han, C. J. (2025) · The Laryngoscope · doi:10.1002/lary.70193 · Cited by 2
GLP ‐1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review
Woo, S., Zhu, G., Castro, C., Phuong, A., Roy, A., Davis, C. N., & Kranzler, H. R. (2026) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70312 · Cited by 3
Beyond Glycemic Control: GLP-1RA–Based Therapies and Emerging Targets Beyond the Metabolic Axis
Matuszewski, W., Wołos-Kłosowicz, K., Włodarczyk, P., Waśniewska, P., Modzelewski, R., Górny, J. M., Szklarz, M., Madeksza, M., & Juranek, J. K. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072786 · Cited by 5
Meraj, A., Koep, L., & Baig, M. R. (2025) · Canadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR · doi:10.29390/001c.127656 · Cited by 1
Ntelis, S., & Wojeck, B. S. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01349-0 · Cited by 1
Obstructive Sleep Apnea and Snoring: Diagnosis, Treatments, and Prognosis
Duenas, S. M., Quintero, L., Iakovou, A., & Greenberg, H. E. (2026) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.12.011 · Cited by 1
Wong, S., Fabiano, N., Zhou, C., Luu, B., Shorr, R., Slassi, S., Solmi, M., Husain, M. I., & Mak, M. S. B. (2025) · Psychiatry International · doi:10.3390/psychiatryint6030111 · Cited by 1
Emdin, M., Gentile, F., & Giannoni, A. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.07.012 · Cited by 1
Sawatari, H., Chishaki, A. S., & Ando, S. (2025) · Sleep And Breathing · doi:10.1007/s11325-025-03447-4 · Cited by 1
Zheng, D., Wu, J., Dai, Y., Chen, L., Chen, B., Zhou, B., Athanasiou, N., Vgontzas, A. N., & Li, Y. (2026) · Thorax · doi:10.1136/thorax-2025-224400 · Cited by 2
Bajpai, J., Saxena, M., Agarwal, U., & Pradhan, A. (2025) · World Journal of Experimental Medicine · doi:10.5493/wjem.v15.i4.109762 · Cited by 1
Prevalence of Obesity Medications in the Military Health System: An Update from 2022
Corrado, R., Meier, M., Banaag, A. L., Neuman, T. J., & Koehlmoos, T. P. (2026) · Military Medicine · doi:10.1093/milmed/usag142 · Cited by 2
Management of Obstructive Sleep Apnea in Epilepsy
Nelliot, A., Rudock, R., & Carosella, C. (2025) · Current Treatment Options in Neurology · doi:10.1007/s11940-025-00859-1 · Cited by 1
Pulmonology: What You May Have Missed in 2024
Alenezy, N., Gu, Y., Saleh, R., Sheriff, L., & UNGER, M. W. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-00797 · Cited by 1
Somasundaram, S., Nightingale, J., Sreedharan, S., & Frauenfelder, C. (2026) · Ear Nose & Throat Journal · doi:10.1177/01455613261445013 · Cited by 1
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1445 · Cited by 1
Mitropoulou, P., Prokšelj, K., Janež, A., Gil, F. R., Verma, S., Jurić, I., Vida, V. L., Gatzoulis, M. Α., & Brida, M. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag067 · Cited by 3
Tipping the Scales: Strategies to Improve Anti‐Obesity Medication Access and Affordability
Komé, A. M., Boykin, A. R., Johnson-Jennings, A., & Coviello, A. D. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70118 · Cited by 1
How Technology Can Increase Access to Sleep Health Care
(2025) · doi:10.1016/j.jsmc.2025.10.011 · Cited by 1
Tirzepatide, Mortality, Cardiovascular, and Renal Outcomes in Sleep Apnea
Mazzotti, D. R., & Stevens, D. R. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.05.019 · Cited by 1
Shahrbabaki, S. S., Mittinty, M., Tonchev, I., Strong, C., Chapman, D., Lorensini, S., Jenkins, E., CATCHESIDE, P. G., Adams, R., Eckert, D. J., et al. (2025) · Heart Rhythm · doi:10.1016/j.hrthm.2025.12.015 · Cited by 2
Malhotra, A., Gottlieb, D. J., Kundel, V., Woehrle, H., Chakladar, S., GONCALVES, L. F., & Calamai, G. (2026) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2026.101660 · Cited by 3
Self-citationSaeed, Z. I., & Apovian, C. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01369-w · Cited by 2
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Son, J. W. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0138 · Cited by 1
Perceptions and stigma of anti-obesity pharmacotherapy in adult Polish women
Witaszek, T., Kłoda, K., Mastalerz-Migas, A., & Babicki, M. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1687120 · Cited by 1
CPAP Therapy for OSA and Its Impact on Various Cardiovascular Disorders
Kumari, K., Khalaf, J., Sawan, L. J., Ho, W. L., Murugan, C. K., Gupta, A., Devani, A., Rizwan, M., Kaku, R., Muzammil, M. A., et al. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000843 · Cited by 5
Xiao-yu, Z., Deng, C.-H., Zhong, J.-Y., Wu, Q., Chen, Q.-X., Gao, X.-Y., Xu, Y., Jiang, Z., Guo, M., & Teng, F. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104859 · Cited by 1
Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies
Abburi, K., Melson, E., Miras, A. D., & Papamargaritis, D. (2025) · Panminerva Medica · doi:10.23736/s0031-0808.25.05339-x · Cited by 1
OSA, CPAP, and the impact on cardiometabolic parameters: what is next?
Drager, L. F. (2025) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2025.102213 · Cited by 2
Rodríguez‐Martín, M., Szczerbiński, Ł., Garaulet, M., & Dashti, H. S. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.09.010 · Cited by 1
Al-Houqani, M., Alzaki, M. H., & Agha, A. (2026) · Sleep And Breathing · doi:10.1007/s11325-026-03623-0 · Cited by 2
State of the Art Review: Glucagon-Like Peptide-1 in Obesity-Related Asthma
Gomez, D. R., Swartzman, I., Linderholm, A., Cummings, B. P., Zeki, A. A., Sundar, K. M., & Kenyon, N. J. (2025) · Lung · doi:10.1007/s00408-025-00861-z · Cited by 3
Time to wake up to the potential benefits of targeting sleep in osteoarthritis management
Hall, M., Ferreira, P. H., Eyles, J. P., HAWKER, G. A., Smith, S. S., Egorova, N., McCurry, S. M., Thorlund, J. B., & Klyne, D. M. (2026) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2026.03.122 · Cited by 1
Lingow, S. E., Carris, N. W., Clements, J. N., Courtney, L. A., Lennon, A., Sherrill, C. H., & Dril, E. V. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70111 · Cited by 5
Alicic, R. Z., & Neumiller, J. J. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2024.12.003 · Cited by 1
Clinical Characteristics of Users of Weight Loss Drugs: Population‐Based Case–Control Study
Bakken, I. J., Ruiz, P. L., Furu, K., Gulseth, H. L., Sveen, K. A., Nøkleby, K., Meyer, H. E., Kjerpeseth, L. J., & Karlstad, Ø. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70827 · Cited by 1
Shah, S., Abusafia, M., Sheashaa, H., Jadam, S., Ospina, S., Kaelber, D., Keen, S. K., & Desai, M. Y. (2026) · JACC: Advances · doi:10.1016/j.jacadv.2026.102955
Falcón, B. L., Xie, C. C., Redline, S. S., Grunstein, R., Turnbull, C. D., Rapoport, D. M., Wang, H., Chakladar, S., Dimitriadis, G. K., Lau, E., et al. (2026) · Journal of Clinical Sleep Medicine · doi:10.1007/s44470-026-00162-z
Self-citationPěč, J., Driendl, S., Heinrich, M., Stadler, S., & Arzt, M. E. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-02000-5
A comprehensive review of sleep disordered breathing in people with congenital heart disease
Maxfield, K., Weaver, N., Wei, M., Matloff, D., Partha, M., Seckeler, M. D., & Combs, D. (2026) · Frontiers in Sleep · doi:10.3389/frsle.2026.1857984
Obstructive sleep apnea: understanding endophenotypes for precision medicine
Liu, W. L., Yang, C., & Mao, W. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.09.003
Bariatric Surgery, Medical Weight Loss, and the Upper Aerodigestive Tract
Samreen, S., & Hutter, M. M. (2026) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2026.08.001
Pharmacotherapy for Precision Medicine of Obstructive Sleep Apnea
Bao, W., Ren, R., Ren, S., Tang, X., & Zhang, Y. (2026) · Journal of Sleep Research · doi:10.1111/jsr.70379
Weight loss in older adults with obstructive sleep apnea: beneficial or harmful?
Nowalk, N. C., Keenan, B. T., Mokhlesi, B., & Schwab, R. (2025) · SLEEP · doi:10.1093/sleep/zsaf413
Self-citationDuong‐Quy, S., Chirakalwasan, N., Desudchit, T., Liu, S. Y., Chai, L. L., Dang‐Vu, T. T., Kadotani, H., Kim, S., Yang, H. C., Dizon, R. V., et al. (2026) · Pulmonary Therapy · doi:10.1007/s41030-026-00386-7
Metadata
- Authors
- Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., Bunck, M. C., & Bednarik, J.
- Affiliations
- Brigham and Women's Hospital (US)
- From the University of California, San Diego, La Jolla (A.M.); Woolcock Institute of Medical Research, Macquarie University, Royal Prince Alfred Hospital, and the University of Sydney — all in Sydney (R.R.G.); the Center of Sleep Medicine, Charité University Hospital Berlin, Berlin (I.F.); the College of Nursing, University of Illinois Chicago, Chicago (T.E.W.); the School of Nursing (T.E.W.) and Perelman School of Medicine (R.J.S.), University of Pennsylvania, Philadelphia; the Division of Sleep and Circadian Disorders, Brigham and Women’s Hospital, and Harvard Medical School — both in Boston (S.R., A.A., S.A.S.); and Eli Lilly, Indianapolis (J.P.D., S.C., M.C.B., J.B.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-03
- Volume
- 391
- Issue
- 13
- Pages
- 1193-1205
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC11598664
- OpenAlex
- W4399907994
- Cited by
- 871
- References
- 39
- Citations by year
- 2026: 410 · 2025: 379 · 2024: 80
- FWCI
- 245.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Apelin-related biomedical research
- Keywords
- tirzepatide, obstructive sleep apnea, obesity, GLP-1 receptor agonists, GIP receptor agonist, apnea-hypopnea index, weight loss, positive airway pressure, hypoxic burden, sleep disorders, C-reactive protein, systolic blood pressure, cardiovascular risk, anti-obesity drugs, obesity-related sleep apnea, body mass index
- MeSH terms
- Sleep Quality, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Adult, Hypoxia, Blood Pressure, Body Weight, C-Reactive Protein, Double-Blind Method, Female, Gastric Inhibitory Polypeptide, Humans, Male, Middle Aged, Obesity, Severity of Illness Index, Treatment Outcome, Sleep Apnea, Obstructive, Maximum Tolerated Dose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.